Neurocrine Biosciences
NBIX
#1662
Rank
NZ$21.80 B
Marketcap
NZ$216.78
Share price
-0.48%
Change (1 day)
21.61%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): NZ$8.23

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$8.20. an increase over its 2024 EPS that were of NZ$5.75.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025NZ$7.9337.87%
2024NZ$5.7533.07%
2023NZ$4.3257.76%
2022NZ$2.7469.47%
2021NZ$1.62-78.21%
2020NZ$7.42990%
2019NZ$0.6881.82%
2018NZ$0.37-113.5%
2017NZ-$2.770.62%
2016NZ-$2.7657.28%
2015NZ-$1.7525.61%
2014NZ-$1.3918.84%
2013NZ-$1.17-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.31-71.78%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$4.07-50.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$39.17 377.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$1.48-81.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.45-142.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$2.91-64.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ-$50.87-720.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.99-63.56%๐Ÿ‡ฌ๐Ÿ‡ง UK